China Pharma (CPHI) Competitors

Bio-Path (NASDAQ:BPTH) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, community ranking, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

Do insiders and institutionals have more ownership in BPTH or CPHI?

5.7% of Bio-Path shares are held by institutional investors. 3.1% of Bio-Path shares are held by company insiders. Comparatively, 46.0% of China Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community favor BPTH or CPHI?

Bio-Path received 281 more outperform votes than China Pharma when rated by MarketBeat users. Likewise, 55.64% of users gave Bio-Path an outperform vote while only 0.00% of users gave China Pharma an outperform vote.

Company	Underperform	Outperform
Bio-Path	Outperform Votes 281 55.64%	Underperform Votes 224 44.36%
China Pharma	Outperform Votes No Votes	Underperform Votes 45 100.00%

Which has higher valuation and earnings, BPTH or CPHI?

China Pharma has higher revenue and earnings than Bio-Path.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$40.80	-0.10
China Pharma	$7.01M	0.69	-$3.08M	N/A	N/A

Does the media prefer BPTH or CPHI?

In the previous week, Bio-Path had 17 more articles in the media than China Pharma. MarketBeat recorded 18 mentions for Bio-Path and 1 mentions for China Pharma. China Pharma's average media sentiment score of 0.17 beat Bio-Path's score of 0.00 indicating that Bio-Path is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Path	1 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility and risk, BPTH or CPHI?

Bio-Path has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, China Pharma has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.

Is BPTH or CPHI more profitable?

Bio-Path has a net margin of 0.00% compared to Bio-Path's net margin of -43.91%. Bio-Path's return on equity of -54.53% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-375.74%	-248.63%
China Pharma	-43.91%	-54.53%	-18.98%

Do analysts recommend BPTH or CPHI?

Bio-Path currently has a consensus target price of $40.00, indicating a potential upside of 989.92%. Given China Pharma's higher probable upside, research analysts clearly believe Bio-Path is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Summary

Bio-Path beats China Pharma on 8 of the 14 factors compared between the two stocks.